Actuate Therapeutics Inc (ACTU) vs Estrella Immunopharma, Inc. (ESLA)
A side-by-side comparison of Actuate Therapeutics Inc and Estrella Immunopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACTU
Actuate Therapeutics Inc
$0.81HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ESLA
Estrella Immunopharma, Inc.
$0.43HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ACTU vs ESLA
growth of $100 · dividends reinvested · last 2yACTU -89.8% (-68.1%/yr)ESLA -69.2% (-44.5%/yr)ESLA compounded faster over this window
ACTU ESLA
ACTU vs ESLA: by the numbers
- •ACTU is the larger company ($19M vs $18M market cap).
Metrics side by side
Valuation
| Metric | ACTU | ESLA |
|---|---|---|
| P/B ratio | 19.63 | N/A |
Profitability
| Metric | ACTU | ESLA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -2067.81% | N/A |
| ROIC | -1489.99% | N/A |
Growth (annualized)
| Metric | ACTU | ESLA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -46.34% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.